SCHEMBL5651264

SCHEMBL5651264

O=C(NCCCN1CCOCC1)c1ccc(-c2nc3cc(F)c(Cl)cc3[nH]2)s1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 3/20 0.48
HSD17B10 Q99714 3/20 0.48
HPGD P15428 2/20 0.48
TP53 P04637 1/20 0.48
GAA P10253 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
STAT3 P40763 1/20 0.46
RAB9A P51151 1/20 0.46
GLA P06280 1/20 0.45
KLK7 P49862 1/20 0.44
TSHR P16473 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651258 0.97 L3MBTL1 (0.51) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL5652813 0.90 L3MBTL1 (0.51) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL5652805 0.89 MEN1 (0.51) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL5648386 0.84 FLT3 (0.44) KDM4EHSD17B10
SCHEMBL5648739 0.84 HDAC3 (0.51) ALDH1A1KDM4ETSHRMAPK1
SCHEMBL5651069 0.84 MEN1 (0.51) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL5651073 0.84 MEN1 (0.51) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL5653211 0.83 MET (0.51) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL5648730 0.81 HDAC3 (0.51) ALDH1A1KDM4ETSHRMAPK1
SCHEMBL5648383 0.81 FLT3 (0.44) KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 L3MBTL1 1534/4885MEN1 3545/4885KMT2A 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.